GLP-1 Receptor Agonists (2026 Review, PMC) and What Changes in Clinical Practice

Read this article in Spanish: Spanish Version

Pediatric obesity is associated with insulin resistance, dyslipidemia, hypertension, sleep apnea, liver dysfunction, and significant psychosocial distress. When obesity progresses during adolescence, its “carryover effect” into adulthood substantially increases the risk of type 2 diabetes and cardiovascular disease. For this reason, obesity treatment is now understood as chronic disease management: clear diagnosis, active screening for comorbidities, intensive family-based intervention, and, in selected cases, pharmacotherapy.

In this context, GLP-1 receptor agonists (GLP-1 RAs) represent a major paradigm shift. Their therapeutic mechanism is based on modulation of the gut-brain axis through delayed gastric emptying and activation of anorexigenic neural pathways, leading to reduced hunger and improvement in metabolic markers.

The 2026 review published in PMC summarizes robust clinical evidence showing that, in adolescents, GLP-1 receptor agonists can achieve clinically meaningful BMI reductions when combined with lifestyle intervention. The review highlights important trial outcomes: weekly semaglutide 2.4 mg combined with lifestyle intervention demonstrated substantial average BMI reductions compared with placebo, with a high proportion of participants achieving ≥5% and ≥10% weight reduction. Daily liraglutide 3.0 mg also produced greater BMI reduction than lifestyle intervention alone, although gastrointestinal side effects were more frequent.

One clinically important point is that weight regain may occur after discontinuation of the medication, reinforcing the concept that obesity management should be approached as long-term chronic care rather than a short-term intervention.

My interpretation as a pediatric epidemiologist is twofold. On an individual level, GLP-1 receptor agonists open an important therapeutic window for adolescents with moderate to severe obesity and associated comorbidities, especially when well-structured behavioral interventions alone are insufficient because of the biological defense mechanisms of body weight. However, their use requires careful patient selection, realistic expectation management — with emphasis on sustainable cardiometabolic health rather than rapid cosmetic change — and close monitoring of gastrointestinal tolerance, mental health, access, and continuity of care.

From a population health perspective, inequity remains a major concern. The review notes the increasing prescription rates of GLP-1 medications in the United States, but also highlights that the proportion of adolescents with obesity who actually receive pharmacologic treatment remains very low, suggesting significant barriers related to cost, insurance coverage, and availability. This raises the risk of widening health disparities if only certain groups can maintain long-term therapy.

The ethical response is not to slow innovation, but to integrate these therapies into accessible, intensive multidisciplinary programs alongside public health policies aimed at reducing exposure to ultra-processed foods, sedentary lifestyles, and unhealthy environments. In other words, GLP-1 therapies do not replace family-based intervention or public health strategies; they complement them when cardiometabolic risk justifies treatment and when healthcare systems can provide continuity of care.